Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.53 |
| ▸ | HPGDS | O60760 | 2/20 | 0.47 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.46 |
| ▸ | TTK | P33981 | 2/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | LIPC | P11150 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20280701 | 0.92 | MET (0.52) | METHPGDSIRAK1TTKFGFR1 | |
| SCHEMBL15431560 | 0.92 | GPR119 (0.55) | METHPGDSIRAK1TTKFGFR1 | |
| SCHEMBL16899750 | 0.91 | MET (0.51) | METHPGDSIRAK1TTKFGFR1 | |
| SCHEMBL16907836 | 0.91 | MET (0.51) | METHPGDSIRAK1TTKFGFR1 | |
| SCHEMBL15416687 | 0.90 | MET (0.51) | METHPGDSIRAK1TTKFGFR1 | |
| SCHEMBL15415993 | 0.90 | GPR119 (0.54) | METHPGDSIRAK1TTKFGFR1 | |
| SCHEMBL16899801 | 0.89 | MET (0.51) | METHPGDSIRAK1TTKFGFR1 | |
| SCHEMBL15431641 | 0.89 | GPR119 (0.52) | METHPGDSIRAK1TTKFGFR1 | |
| SCHEMBL15416250 | 0.89 | MET (0.49) | METHPGDSIRAK1TTKFGFR1 | |
| SCHEMBL15416081 | 0.88 | MET (0.54) | METHPGDSIRAK1TTKFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872501-B1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING SA (CH) | 2016-06-01 | — | — | EP | disclosed |
| US-9216991-B2 | Pyrimidine pyrazolyl derivatives | ARES TRADING S.A. (CH) | 2015-12-22 | — | — | US | disclosed |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2015-05-21 | — | — | US | disclosed |
| EP-2872501-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | Ares Trading S.A. (CH) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014008992-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | DPYD, TYMS, DHFR | MET 2807/4885HPGDS 143/4885IRAK1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.